Burkholderia pseudomallei Infections (Melioidosis) R&D Pipeline Analysis Report, Q4 2020

October 2020 | 35 pages | ID: B91AEA341B7DEN
VPAResearch

Abstracts

Burkholderia pseudomallei Infections (Melioidosis) Pipeline Overview

The Q4 Burkholderia pseudomallei Infections (Melioidosis) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Burkholderia pseudomallei Infections (Melioidosis), provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Burkholderia pseudomallei Infections (Melioidosis) Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Burkholderia pseudomallei Infections (Melioidosis) disease overview, Burkholderia pseudomallei Infections (Melioidosis) types, Burkholderia pseudomallei Infections (Melioidosis) symptoms, causes, and FDA/EMA approved treatment options.

Burkholderia pseudomallei Infections (Melioidosis) Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Burkholderia pseudomallei Infections (Melioidosis) indication. The report presents near-term and long-term pipeline development trends and potential insights.

Burkholderia pseudomallei Infections (Melioidosis) Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 4 companies. Business profiles and contact details of the companies actively perusing Burkholderia pseudomallei Infections (Melioidosis) pipeline are assessed.

Burkholderia pseudomallei Infections (Melioidosis) R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Burkholderia pseudomallei Infections (Melioidosis) discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Burkholderia pseudomallei Infections (Melioidosis) companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Burkholderia pseudomallei Infections (Melioidosis) pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Burkholderia pseudomallei Infections (Melioidosis) Pipeline Market News and Developments during 2020
The Burkholderia pseudomallei Infections (Melioidosis) industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Burkholderia pseudomallei Infections (Melioidosis) Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

Scope and Coverage

• Burkholderia pseudomallei Infections (Melioidosis) pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
• Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
• Company-company partnerships, company-institute partnerships, and investment details of companies are included
• 4 companies are included including Aradigm Corp, Entasis Therapeutics Inc, MerLion Pharmaceuticals Pte Ltd, Soligenix Inc,
• Disease overview, Pipeline trends, market analysis, and other developments
• Potential licensing/new business opportunities in Burkholderia pseudomallei Infections (Melioidosis) pipeline market

Highlights

• Global coverage of companies and pipeline agents
• 2020 Trends, market analysis, and developments
• Potential growth opportunities
• Comprehensive details of drug candidates

Reasons to Buy

• Drive pipeline research and commercial assessment
• Assess most promising drug candidates and stay ahead of the competition
• Strengthen your pipeline through identifying business expansion and acquisition opportunities
• Develop new candidates based on most focused targets and mechanism of actions

Contents

1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. BURKHOLDERIA PSEUDOMALLEI INFECTIONS (MELIOIDOSIS) PIPELINE TRENDS AND INSIGHTS

2.1 Dominant Phase type of Burkholderia pseudomallei Infections (Melioidosis) Pipeline, 2020
2.2 Most focused Mechanism of Action in Burkholderia pseudomallei Infections (Melioidosis) Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Burkholderia pseudomallei Infections (Melioidosis) pipeline
2.5 Active Companies Developing Burkholderia pseudomallei Infections (Melioidosis) pipeline

3. BURKHOLDERIA PSEUDOMALLEI INFECTIONS (MELIOIDOSIS) DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS

3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options

4. BURKHOLDERIA PSEUDOMALLEI INFECTIONS (MELIOIDOSIS) PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS

4.1 Aradigm Corp
  Entasis Therapeutics Inc
  MerLion Pharmaceuticals Pte Ltd
  Soligenix Inc

5. BURKHOLDERIA PSEUDOMALLEI INFECTIONS (MELIOIDOSIS) PIPELINE DRUG PROFILES

5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
  5.2.1 Drug
  5.2.2 Mechanism of Action
  5.2.3 Phase
  5.2.4 Co-Developer
  5.2.5 Originator
  5.2.6 Synonym
  5.2.7 Route of Administration
  5.2.8 Type of Molecule
  5.2.9 Orphan Drug Status
  5.2.10 New Molecular Entity
  5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details

6. BURKHOLDERIA PSEUDOMALLEI INFECTIONS (MELIOIDOSIS) PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020

7. APPENDIX

7.1 About the Publisher
7.2 Sources and Research Methodology